Wistar Fights COVID-19

Wistar Science. Wistar Legacy.

Ways to Support

Recent Press Releases

View all ›

Wistar Scientists Make Pivotal Discovery on the Mechanism of Epstein-Barr Virus Latent Infection 

New Insights Into the Control of Inflammation 
 

Wistar Researchers Develop New Humanized Mouse Model That Provides Insight Into Immunotherapy Resistance

Our Centers

Maureen and lab

Cancer Center

Wistar is a National Cancer Institute Cancer Center in basic research and has held this designation since 1972.
David and Ami_In the Lab1

Vaccine & Immunotherapy Center

Improving health around the globe by creating and advancing vaccines and immunotherapies.

Upcoming events

View all events ›

Scientific Seminar

Virtual Distinguished Lectures in Cancer Research Series: Mechanisms of Chromosome Folding

Scientific Seminar

Virtual Distinguished Lectures in Cancer Research Series: Altered Protein Glycosylation in Cancer and Roles in Oncogenesis

Scientific Seminar

Virtual Distinguished Lectures in Cancer Research Series: Metabolism, Cellular Decisions and the Language that Unites Them

125 Years of Discovery

View full timeline ›

RotaTeq Approval

The FDA announced the licensing of the rotavirus vaccine developed collaboratively by Wistar, Children’s Hospital of Philadelphia, and Merck & Co., Inc. in the 1980s. The vaccine is sold as ROTATEQ® and is part of the recommended immunization schedule for infants 6 weeks to 32 weeks of age.

View Full Timeline

Accelerating the future

Right now, Wistar Science is making discoveries that will advance human health.

Support Today